RHJA
FATE icon

Rice Hall James & Associates’s Fate Therapeutics FATE Stock Holding History

Rice Hall James & Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-212,864
Closed -$2.15M – 264
2022
Q4 		$2.15M Sell
212,864
-6,282
-3% -$118K 0.12% 182
2022
Q3 		$4.91M Sell
219,146
-53,887
-20% -$1.56M 0.28% 86
2022
Q2 		$6.77M Buy
273,033
+27,117
+11% +$748K 0.33% 71
2022
Q1 		$9.53M Sell
245,916
-4,296
-2% -$166K 0.38% 69
2021
Q4 		$14.6M Sell
250,212
-10,544
-4% -$598K 0.52% 51
2021
Q3 		$15.5M Sell
260,756
-74,671
-22% -$5.86M 0.57% 54
2021
Q2 		$29.1M Sell
335,427
-48,935
-13% -$3.94M 1.04% 29
2021
Q1 		$31.7M Sell
384,362
-2,965
-0.8% -$284K 1.03% 32
2020
Q4 		$35.2M Buy
387,327
+60,483
+19% +$3.76M 1.24% 24
2020
Q3 		$13.1M Buy
+326,844
New +$11.4M 0.53% 53

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Rice Hall James & Associates's FATE Position: Q1 2023 in Review

Rice Hall James & Associates sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 212,864 shares — an estimated $2.15M sold.

Rice Hall James & Associates first reported a position in FATE in Q3 2020 and held it in 10 quarters. The position peaked at $35.2M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Rice Hall James & Associates reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rice Hall James & Associates sold 212,864 Fate Therapeutics shares in Q1 2023, an estimated $2.15M.
  • Rice Hall James & Associates first reported a position in Fate Therapeutics in Q3 2020 and held it in 10 quarters.
  • Rice Hall James & Associates's Fate Therapeutics position peaked at $35.2M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Rice Hall James & Associates's 13F filing for Q1 2023, filed 12 May 2023.